查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
2008665

反义RNAi疗法市场：依寡核苷酸类型、给药途径、治疗领域和最终用户划分－全球市场预测（2026-2032年）

Antisense & RNAi Therapeutics Market by Oligonucleotide Type, Mode Of Administration, Therapeutic Areas, End User - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 180 Pages | 商品交期: 最快1-2个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

预计到 2025 年，反义 RNAi 疗法市场价值将达到 54.6 亿美元，到 2026 年将成长至 62.5 亿美元，到 2032 年将达到 152.3 亿美元，复合年增长率为 15.76%。

主要市场统计数据
预测年份（2025年） 54.6亿美元
基准年（2026 年） 62.5亿美元
预测年份（2032年） 152.3亿美元
复合年增长率（） 15.76%

将分子层面的创新与反义 RNAi 疗法的临床预期联繫起来，以重新定义治疗范式、递送方法和患者结果。

反义和干扰RNA（RNAi）疗法正从小众科学研究走向主流治疗方法，影响多个治疗领域和临床策略。过去十年，化学、递送平台和监管科学的进步，使从分子概念到临床概念验证，最终到核准产品的路径更加清晰。因此，从小规模专业生技公司到大规模综合製药公司，许多相关人员将寡核苷酸平台视为解决以往无法治疗标靶的核心资产。相应地，研发团队目前正努力在早期创新与实际需求（例如生产规模、安全性评估和以病人为中心的给药方案）之间取得平衡。

平台成熟度、监管澄清和协作营运模式正在重塑反义 RNAi 产品的开发和商业化途径。

反义RNAi疗法领域正经历着一场变革，其驱动力包括平台成熟、监管政策的明确性以及更广泛的临床应用目标的整合。平台成熟体现在两个方面：化学方法和结合策略的进步提高了药物的稳定性和疗效，而递送技术的创新则拓展了药物作用于肝臟以外其他组织的途径。这些技术进步降低了标靶选择的传统障碍，使得药物研发计画能够优先考虑患者的便利性和长期用药依从性。因此，药物研发人员正越来越多地探索心血管疾病、代谢性疾病和神经退化性疾病等适应症，而这些疾病先前被认为在技术上或商业性不可行。

本研究评估了美国在 2025 年采取的关税措施对寡核苷酸疗法的原料采购、製造物流和全球供应的影响。

2025年关税措施所营造的政策环境将对寡核苷酸价值链产生重大影响，该价值链涉及原料采购、特殊试剂和关键耗材的跨境贸易。关税若增加进口核苷酸、修饰亚磷酰胺、脂质体配方用脂质以及某些酵素的成本，可能会即时给製造商带来成本压力，影响其扩大生产规模和选择商业生产基地的决策。从长远来看，持续存在的贸易壁垒可能会进一步促进供应链本地化，并鼓励对国内或近岸生产能力进行投资，以降低进口价格波动带来的风险。

细分市场洞察显示寡核苷酸类型、给药途径、治疗标靶和最终用户如何影响研发重点和商业化选择。

细分市场分析能够清楚展现科学机会与商业性可行性的交集，而理解这些细分市场对于确定投资优先顺序和製定商业策略至关重要。根据寡核苷酸的类型，此领域可分为反义寡核苷酸和干扰性RNAi（RNAi）。在干扰性RNAi领域，该计画可进一步细分为微干扰RNA（microIFR）和小干扰RNA（siRNA），二者各自具有独特的效力、剂量假设和递送方式。这些分子差异会影响计画层面的化学性质、结合策略和毒性监测的选择，以及目标组织选择和生物标记策略的发展。

美洲、欧洲、中东和非洲以及亚太地区的区域趋势正在影响研发地点、生产製造、监管和病患取得途径。

区域趋势对研发策略、製造地和市场拓展计画产生了显着影响，导致不同区域形成了各自独特的产能丛集。在美洲，密集的生物技术生态系统和先进的临床基础设施支援快速概念验证（PoC）试验，并推动生产网路的扩张，优先考虑可扩展性和监管合规性。这些条件使该地区成为后期研发和商业化推出的理想之地。同时，创业投资和公共资金的持续涌入也推动了平台技术和First-in-Class项目的创新。

平衡竞争与合作的企业策略：透过合作与平台投资加速产品线成长，扩大 RNA 疗法的生产规模。

寡核苷酸领域的企业发展趋势反映了竞争与合作之间的平衡，策略联盟和平台投资推动了研发管线的加速和生产规模的扩大。该领域的领导企业正投资于化学创新、偶联技术以及递送系统，例如脂质载体和受体靶向偶联物，以扩大其在各机构的覆盖范围并提高安全性。这些投资辅以精心挑选的併购和合作活动，将药物发现能力与后期开发和商业化资源结合。

为产业领导者提供切实可行的策略行动，以优化反义RNAi疗法的交付，降低开发风险，并加速临床部署。

产业领导企业可以采纳一系列优先且切实可行的建议，以增强其反义RNAi计画的韧性并加速价值实现。首先，在药物发现过程的早期阶段就应考虑递送和CMC（化学、生产和品管）因素，以确保平台选择符合可生产性、监管要求和患者用药偏好。早期对化学和製剂进行协同优化可以减少后期返工，并缩短实现可重复且可扩展生产的路径。其次，透过供应商网路多元化和认证取代原材料来源来降低供应链风险。应将受关税影响的原料和关键试剂的情境规划纳入采购和专案风险登记册。

清晰的调查方法概述了应用于反义 RNAi 疗法分析的一级和二级调查、专家访谈和数据三角测量。

本分析采用混合方法研究，结合一手质性研究结果和严谨的二手资料，建构了一个以证据为基础的叙述。主要资料来源包括对药物研发、CMC、临床营运和商业化等领域的专家进行的结构化访谈，这些访谈提供了有关营运挑战、技术应用曲线和策略重点的背景资讯。除这些访谈外，还与生产负责人和法规事务专家进行了有针对性的讨论，以确保为规模化生产的实际问题和合规要求提供切实可行的支援。

一份简洁、全面的分析报告，重点介绍了推动反义 RNAi 疗法发展的相关人员所面临的策略挑战、关键问题和可操作的途径。

本文提出的综合分析凸显了该领域正处于转折点的现状。儘管平台和递送方式的创新正在拓展反义RNAi疗法的临床应用，但也增加了商业性和营运的复杂性。关键挑战包括平台选择和可製造性匹配、建立能够应对贸易和关税不确定性的弹性供应链，以及设计能够满足支付方和医疗服务提供者循证需求的临床项目。具备科学抱负、严谨的营运执行力和策略伙伴关係关係的相关人员，将更有能力将技术进步转化为对病患和企业都可持续的成果。

目录

第一章 引言

第二章 分析方法

  • 分析设计
  • 分析框架
  • 市场规模预测
  • 数据三角测量
  • 分析结果
  • 分析的前提条件
  • 分析的局限性

第三章执行摘要

  • 首席体验长的观点
  • 市场规模和成长趋势
  • 市占率分析（2025 年）
  • FPNV定位矩阵（2025）
  • 新的商机
  • 下一代经营模式
  • 产业蓝图

第四章 市场概览

  • 产业生态系与价值链分析
  • 波特五力分析
  • PESTEL 分析
  • 市场展望
  • 市场进入（GTM）策略

第五章 市场洞察

  • 消费者分析与最终用户观点
  • 消费者体验基准测试
  • 机会映射
  • 分销通路分析
  • 价格趋势分析
  • 监理合规和标准框架
  • ESG与永续性分析
  • 中断和风险情景
  • 成本效益分析（ROI）和成本效益分析（CBA）

第六章：美国关税的累积影响（2025 年）

第七章：人工智慧（AI）的累积影响（2025 年）

第八章：反义RNAi疗法市场：以寡核苷酸类型划分

  • 反义寡核苷酸
  • 干扰RNAi
    • 微干扰RNA
    • 小干扰RNA

第九章：反义RNAi疗法市场：依给药途径划分

  • 鞘内腔
  • 静脉
  • 口服
  • 皮下
  • 外用

第十章：反义RNAi治疗市场：依治疗领域划分

  • 循环系统
  • 免疫学
  • 代谢性疾病
  • 神经系统疾病
  • 瘤
  • 眼科
  • 罕见疾病

第十一章 反义RNAi疗法市场：以最终用户划分

  • CRO（委外研发机构）
  • 製药公司
  • 研究机构

第十二章 反义RNAi疗法市场：按地区划分

  • 北美洲和南美洲
    • 北美洲
    • 拉丁美洲
  • 欧洲、中东和非洲
    • 欧洲
    • 中东
    • 非洲
  • 亚太地区

第十三章 反义RNAi疗法市场：依组别划分

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第十四章 反义RNAi疗法市场：依国家划分

  • 我们
  • 加拿大
  • 墨西哥
  • 巴西
  • 英国
  • 德国
  • 法国
  • 俄罗斯
  • 义大利
  • 西班牙
  • 中国
  • 印度
  • 日本
  • 澳洲
  • 韩国

第十五章：美国反义RNAi疗法市场

第十六章：中国反义RNAi疗法市场

第十七章 竞争格局

  • 市场集中度分析（2025 年）
    • 浓度比（CR）
    • 赫芬达尔-赫希曼指数 (HHI)
  • 近期趋势及影响分析（2025 年）
  • 产品系列分析（2025 年）
  • 基准分析（2025 年）
  • Acuitas Therapeutics Inc.
  • Alloy Therapeutics, Inc.
  • Alnylam Pharmaceuticals, Inc.
  • Arbutus Biopharma Corporation
  • Arrowhead Pharmaceuticals, Inc.
  • AstraZeneca plc
  • Bayer AG
  • Benitec Biopharma Limited
  • City Therapeutics
  • Danaher Corporation
  • Eli Lilly and Company
  • Evox Therapeutics Ltd
  • GenScript Biotech Corporation
  • GSK PLC
  • Ionis Pharmaceuticals, Inc.
  • Merck KGaA
  • Novo Nordisk A/S
  • Pfizer Inc.
  • Ribocure Pharmaceuticals AB
  • Sanofi SA
  • Shanghai Argo Biopharmaceutical Co., Ltd.
  • Silence Therapeutics plc
  • Stoke Therapeutics, Inc.
  • Suzhou Ribo Life Science Co., Ltd.
  • Wave Life Sciences Ltd
Product Code: MRR-8E22B61932A7

The Antisense & RNAi Therapeutics Market was valued at USD 5.46 billion in 2025 and is projected to grow to USD 6.25 billion in 2026, with a CAGR of 15.76%, reaching USD 15.23 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 5.46 billion
Estimated Year [2026] USD 6.25 billion
Forecast Year [2032] USD 15.23 billion
CAGR (%) 15.76%

Bridging molecular innovation and clinical promise in antisense and RNAi therapeutics to redefine treatment paradigms, delivery, and patient outcomes

Antisense and RNA interference (RNAi) therapeutics are transitioning from a niche scientific pursuit into a mainstream modality influencing multiple therapeutic areas and clinical strategies. Over the past decade, advances in chemistry, delivery platforms, and regulatory science have brought a clearer line of sight from molecular concept to clinical proof of concept, and increasingly to approved products. As a result, stakeholders ranging from small specialized biotechs to large, integrated pharmaceutical companies view oligonucleotide platforms as core assets for addressing previously intractable targets. Consequently, development teams are now balancing early-stage innovation with the practicalities of manufacturing scale, safety characterization, and patient-centric administration.

At the same time, clinical programs are diversifying. Research now extends beyond rare genetic diseases into more prevalent therapeutic segments where modulation of gene expression offers differentiated mechanisms of action. This expansion has been enabled by technologies that improve tissue targeting, reduce off-target effects, and enable lower dosing frequencies, thereby strengthening the clinical and commercial rationale for antisense oligonucleotides and RNAi agents. Further, improvements in analytical methods and preclinical models have increased confidence in translational choices, enabling a faster, more iterative path from bench to clinic.

Importantly, the evolving landscape requires integrated thinking: scientific innovation must be matched by supply chain resilience, regulatory engagement, and payer-forward evidence generation. As development cycles compress and regulatory pathways become better-understood, program teams must orchestrate cross-functional alignment early and execute with heightened operational rigor. This introduction sets the stage for a deeper exploration of the transformative shifts reshaping the field, the policy and trade dynamics that affect global supply chains, and the practical segmentation and regional nuances leaders must account for when designing portfolios and commercialization strategies.

Platform maturation regulatory clarity and collaborative operational models that are reshaping antisense and RNAi product development and commercialization pathways

The antisense and RNAi therapeutic landscape is undergoing transformative shifts driven by convergence of platform maturation, regulatory clarity, and broader clinical ambition. Platform maturation has been twofold: chemistry and conjugate strategies have improved stability and potency, while delivery innovations have extended reach into tissues beyond the liver. These technical advances have reduced historical barriers to target selection and enabled programs that prioritize patient convenience and long-term adherence. As a result, drug developers are increasingly exploring indications in cardiovascular, metabolic, and neurodegenerative diseases that were previously considered technically or commercially infeasible.

Regulatory pathways are also adapting, with agencies demonstrating greater familiarity with oligonucleotide-specific risks and benefit profiles. This familiarity permits more predictable interactions around nonclinical packages, biomarker strategy, and safety monitoring, which, in turn, shortens the cycle from early human trials to pivotal studies. In parallel, clinical trial design is becoming more adaptive and biomarker-driven, supporting enriched patient selection and clearer demonstration of mechanism. Consequently, sponsors are leveraging translational endpoints and real-world evidence frameworks to build payer-relevant dossiers earlier in development.

Commercial and operational behaviors are aligning with these scientific and regulatory shifts. Developers are prioritizing manufacturing scalability and advanced analytics to de-risk CMC activities, while partnerships and alliances link clinical capabilities with specialized contract development and manufacturing organizations. These collaborative structures enable smaller sponsors to retain strategic control of their science while accessing the industrial capabilities necessary to move programs through late-stage development and into the market. Taken together, these shifts are expanding the definition of clinical viability and redefining strategic playbooks across research, development, and commercialization.

Evaluating how 2025 US tariff actions could reshape raw material sourcing, manufacturing logistics, and global supply of oligonucleotide therapeutics

The policy environment created by tariff measures in 2025 has important implications for the oligonucleotide value chain, where raw material sourcing, specialized reagents, and critical consumables traverse international borders. Tariffs that raise the cost of imported nucleotides, modified phosphoramidites, lipids used in lipid nanoparticle formulations, and select enzymes could create immediate cost pressure for manufacturers and impact decisions about where to site process scale-up and commercial production. Over time, sustained trade barriers can encourage greater regionalization of supply chains and foster investment in domestic or nearshore production capacity to mitigate exposure to import volatility.

Operationally, higher import costs will often translate into longer procurement lead times as buyers consolidate orders to achieve scale or requalify multiple suppliers for redundancy. In turn, this behavior places a premium on supplier relationship management, quality oversight, and inventory policies. For sponsors and contract manufacturers, the strategic response may include securing multi-year contracts, investing in alternate chemistries that reduce reliance on tariff-exposed inputs, or accelerating vertical integration strategies where feasible. Regulatory timelines for process changes must also be considered, as re-sourcing critical raw materials can require additional process validation and regulatory communications, potentially constraining the flexibility of clinical supply strategies.

Strategically, tariff-induced shifts can yield both challenge and opportunity. While cost increases present near-term headwinds, they can motivate investments in domestic manufacturing capacity, regional talent development, and improved process efficiencies that strengthen long-term supply resilience. Moreover, policy uncertainty typically increases the value of diversified sourcing and robust risk management programs. Consequently, organizations that proactively model tariff scenarios, incorporate contingency options into procurement and manufacturing plans, and engage with policy stakeholders where appropriate will be better positioned to maintain development momentum despite trade disruptions.

Segmentation insights demonstrating how oligonucleotide type, administration mode, therapeutic targets, and end users shape R&D focus and commercialization choices

Segmentation analysis provides clarity on where scientific opportunity and commercial viability intersect, and understanding these segments is critical for prioritizing investment and operational design. Based on Oligonucleotide Type, the landscape differentiates antisense oligonucleotides and interfering RNAi; within interfering RNAi, programs further distinguish between micro interfering RNAs and small interfering RNAs, each with distinct potency, dosing expectations, and delivery considerations. These molecular distinctions drive program-level choices in chemistry, conjugation strategies, and toxicity monitoring, and also inform the selection of tissue targets and biomarker strategies.

Based on Mode Of Administration, development paths and patient adoption profiles diverge significantly across intrathecal, intravenous, oral, subcutaneous, and topical routes. Administration mode influences formulation science, cold chain and logistics requirements, and the design of clinical operations; for example, intrathecal and intravenous routes often necessitate facility-based administration and more complex safety monitoring, while subcutaneous and oral options support decentralized models that can improve patient retention and real-world uptake. As a result, companies must weigh the trade-offs between clinical efficacy, patient convenience, and the downstream implications for reimbursement and market access.

Based on Therapeutic Areas, program portfolios reflect a breadth of indication choices, spanning cardiovascular, immunology, metabolic disorders, neurological disorders, oncology, ophthalmology, and rare diseases. Each therapeutic area carries unique regulatory expectations, clinical endpoint challenges, and competitive dynamics. For instance, neurology and rare disease programs may rely heavily on validated biomarkers and patient registries, whereas oncology and cardiovascular initiatives may require larger, event-driven trials and differentiated value propositions for payers. Strategic alignment between therapeutic focus and platform strengths is therefore a core determinant of program design and resource allocation.

Based on End User, the market's ecosystem includes contract research organizations, pharmaceutical companies, and research laboratories that collectively shape innovation cycles and commercialization pathways. Contract research organizations play an increasingly central role in providing specialized development and manufacturing capabilities that lower barriers for sponsors. Pharmaceutical companies contribute commercial scale, regulatory expertise, and payer engagement capabilities, while research laboratories drive early discovery and mechanistic understanding. The interplay among these end users determines how capabilities are assembled, how risks are shared, and how innovations ultimately reach patients.

Regional dynamics across the Americas, Europe Middle East & Africa, and Asia-Pacific shaping development hubs, manufacturing, regulations, and patient access

Regional dynamics exert outsized influence on development strategies, manufacturing footprints, and go-to-market planning, with distinct capability clusters emerging across geographies. In the Americas, dense biotech ecosystems and advanced clinical infrastructure support rapid proof-of-concept studies and growing manufacturing networks that prioritize scale and regulatory familiarity. These conditions make the region attractive for late-stage development and commercial launches, while access to venture and public capital continues to drive innovation in platform technologies and first-in-class programs.

In Europe, Middle East & Africa, a mix of academic excellence, regulatory harmonization within certain jurisdictions, and evolving industrial policy encourages partnerships and center-of-excellence models. Sponsors targeting these markets often coordinate multi-jurisdictional regulatory strategies and leverage regional manufacturing hubs to serve multiple neighboring markets efficiently. Policy incentives and public-private collaborations in parts of this region also encourage investment in capacity expansion and advanced analytics.

Across Asia-Pacific, capacity expansion, government-supported industrial initiatives, and a rapidly maturing clinical research environment are reshaping supply and demand dynamics. Increasing local manufacturing capabilities and talent pools create opportunities for nearshore sourcing and regional clinical acceleration. Consequently, many organizations are evaluating hybrid development models that combine western clinical development with Asia-Pacific manufacturing or clinical execution to optimize timelines, cost, and patient recruitment. Taken together, these regional patterns underscore the importance of aligning portfolio design with geographic strengths to optimize development velocity and commercial access.

Competitive and collaborative company strategies alliances and platform investments accelerating pipelines and scaling manufacturing for RNA-based therapies

Company behaviors in the oligonucleotide sector reflect a balance of competition and collaboration, with strategic alliances and platform investments driving acceleration of pipelines and scaling of manufacturing. Leaders in the space are investing in chemistry innovations, conjugate technologies, and delivery systems such as lipid-based carriers or receptor-targeting conjugates to expand tissue reach and improve safety margins. These investments are complemented by selective M&A and partnership activity that brings together discovery capabilities with late-stage development and commercialization resources.

Beyond scientific investments, companies are making deliberate choices about how to structure manufacturing operations. Some sponsors opt to partner with specialized contract development and manufacturing organizations to access scale quickly, while others pursue vertically integrated models to retain greater control over critical process steps and supply security. In either case, investments in analytical capabilities, process automation, and regulatory-ready quality systems are common priorities, as they materially reduce the time and risk associated with scale-up and commercial release.

Collaboration extends to payer and provider engagement as well. Forward-looking companies are modeling long-term value propositions that incorporate dosing convenience, durability of effect, and real-world outcomes to build evidence packages that resonate with health systems. Partnerships that align clinical development with payer expectations and delivery systems enhance the probability of favorable access conditions and smoother rollout strategies. Overall, corporate strategies emphasize platform differentiation, manufacturing resilience, and cross-sector engagement to convert scientific potential into durable clinical and commercial success.

Practical strategic actions for industry leaders to optimize delivery, de-risk development, and accelerate clinical adoption of antisense and RNAi therapies

Industry leaders can pursue a set of prioritized, actionable recommendations to enhance resilience and accelerate value realization across antisense and RNAi programs. First, integrate delivery and CMC considerations early in the discovery process so that platform choices align with manufacturability, regulatory expectations, and patient administration preferences. Early co-optimization of chemistry and formulation reduces late-stage rework and shortens the path to reproducible, scalable manufacturing. Second, diversify supplier networks and qualify alternate raw material sources to mitigate supply chain risk; scenario planning for tariff-impacted inputs and critical reagents should be embedded into procurement and program risk registers.

Third, pursue collaborative models that leverage specialized CDMOs and research partners to access capacity and technical expertise without overextending capital deployment. Strategic alliances that include shared development milestones and de-risking mechanisms can accelerate timelines while preserving upside for original innovators. Fourth, design clinical programs with payer-relevant endpoints and real-world evidence components that anticipate market access questions earlier in development; this alignment increases the probability of reimbursement and supports broader adoption post-launch. Fifth, invest in regulatory strategy and proactive engagement with authorities to clarify expectations around nonclinical safety, biomarker qualification, and comparability as manufacturing scales. Proactive regulatory planning reduces uncertainty and supports more efficient submission packages.

Finally, prioritize workforce capability building and cross-functional governance to manage complex development portfolios effectively. Establish multidisciplinary teams that align discovery, translational science, CMC, clinical operations, and commercial planning to ensure decisions are made with a holistic view of program risks and opportunities. Collectively, these actions create a practical roadmap for leaders seeking to translate molecular promise into patient impact while controlling development complexity and commercial risk.

Clear research methodology outlining primary and secondary approaches expert interviews and data triangulation applied to antisense and RNAi therapeutic analysis

This analysis is grounded in a mixed-methods research approach that combines primary qualitative insights and rigorous secondary synthesis to create an evidence-based narrative. Primary inputs include structured interviews with subject-matter experts across discovery, CMC, clinical operations, and commercial functions, which offer context on operational challenges, technology adoption curves, and strategic priorities. These conversations were supplemented by targeted consultations with manufacturing leaders and regulatory affairs specialists to ensure practical grounding in scale-up realities and compliance expectations.

Secondary research entailed systematic review of peer-reviewed literature, regulatory guidance documents, public company disclosures, and technical white papers that illuminate technology advances, safety considerations, and clinical trends. Data from diverse sources were triangulated to identify consistent signals, reconcile differences, and highlight areas of emerging consensus or uncertainty. Throughout the process, findings were validated against expert perspectives to refine interpretation, ensure factual accuracy, and surface actionable implications for decision-makers.

Concise synthesis highlighting strategic imperatives key challenges and practical pathways for stakeholders advancing antisense and RNAi therapeutic development

The synthesis presented here underscores a sector at an inflection point: platform and delivery innovations are broadening the clinical applicability of antisense and RNAi modalities even as commercial and operational complexities increase. Key imperatives include aligning platform choices with manufacturability, building resilient supply chains that account for trade and tariff uncertainty, and designing clinical programs that address payer and provider evidence needs. Stakeholders who combine scientific ambition with disciplined operational execution and strategic partnerships will be best positioned to convert technical advances into durable patient and commercial outcomes.

Persistent challenges remain, including tissue-specific delivery beyond canonical targets, long-term safety characterization, and the logistical demands of scalable manufacturing. Nonetheless, by prioritizing early alignment across discovery, CMC, and clinical functions and by proactively managing external risks such as trade policy shifts, organizations can navigate the complexity and capture the value this therapeutic class offers. The conclusion is pragmatic: success will favor those who pair innovation with operational foresight and market-oriented evidence generation.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Antisense & RNAi Therapeutics Market, by Oligonucleotide Type

  • 8.1. Antisense Oligonucleotides
  • 8.2. Interfering RNAi
    • 8.2.1. Micro Interfering RNAs
    • 8.2.2. Small Interfering RNAs

9. Antisense & RNAi Therapeutics Market, by Mode Of Administration

  • 9.1. Intrathecal
  • 9.2. Intravenous
  • 9.3. Oral
  • 9.4. Subcutaneous
  • 9.5. Topical

10. Antisense & RNAi Therapeutics Market, by Therapeutic Areas

  • 10.1. Cardiovascular
  • 10.2. Immunology
  • 10.3. Metabolic Disorders
  • 10.4. Neurological Disorders
  • 10.5. Oncology
  • 10.6. Ophthalmology
  • 10.7. Rare Diseases

11. Antisense & RNAi Therapeutics Market, by End User

  • 11.1. Contract Research Organizations
  • 11.2. Pharmaceutical Companies
  • 11.3. Research Laboratories

12. Antisense & RNAi Therapeutics Market, by Region

  • 12.1. Americas
    • 12.1.1. North America
    • 12.1.2. Latin America
  • 12.2. Europe, Middle East & Africa
    • 12.2.1. Europe
    • 12.2.2. Middle East
    • 12.2.3. Africa
  • 12.3. Asia-Pacific

13. Antisense & RNAi Therapeutics Market, by Group

  • 13.1. ASEAN
  • 13.2. GCC
  • 13.3. European Union
  • 13.4. BRICS
  • 13.5. G7
  • 13.6. NATO

14. Antisense & RNAi Therapeutics Market, by Country

  • 14.1. United States
  • 14.2. Canada
  • 14.3. Mexico
  • 14.4. Brazil
  • 14.5. United Kingdom
  • 14.6. Germany
  • 14.7. France
  • 14.8. Russia
  • 14.9. Italy
  • 14.10. Spain
  • 14.11. China
  • 14.12. India
  • 14.13. Japan
  • 14.14. Australia
  • 14.15. South Korea

15. United States Antisense & RNAi Therapeutics Market

16. China Antisense & RNAi Therapeutics Market

17. Competitive Landscape

  • 17.1. Market Concentration Analysis, 2025
    • 17.1.1. Concentration Ratio (CR)
    • 17.1.2. Herfindahl Hirschman Index (HHI)
  • 17.2. Recent Developments & Impact Analysis, 2025
  • 17.3. Product Portfolio Analysis, 2025
  • 17.4. Benchmarking Analysis, 2025
  • 17.5. Acuitas Therapeutics Inc.
  • 17.6. Alloy Therapeutics, Inc.
  • 17.7. Alnylam Pharmaceuticals, Inc.
  • 17.8. Arbutus Biopharma Corporation
  • 17.9. Arrowhead Pharmaceuticals, Inc.
  • 17.10. AstraZeneca plc
  • 17.11. Bayer AG
  • 17.12. Benitec Biopharma Limited
  • 17.13. City Therapeutics
  • 17.14. Danaher Corporation
  • 17.15. Eli Lilly and Company
  • 17.16. Evox Therapeutics Ltd
  • 17.17. GenScript Biotech Corporation
  • 17.18. GSK PLC
  • 17.19. Ionis Pharmaceuticals, Inc.
  • 17.20. Merck KGaA
  • 17.21. Novo Nordisk A/S
  • 17.22. Pfizer Inc.
  • 17.23. Ribocure Pharmaceuticals AB
  • 17.24. Sanofi S.A.
  • 17.25. Shanghai Argo Biopharmaceutical Co., Ltd.
  • 17.26. Silence Therapeutics plc
  • 17.27. Stoke Therapeutics, Inc.
  • 17.28. Suzhou Ribo Life Science Co., Ltd.
  • 17.29. Wave Life Sciences Ltd

LIST OF FIGURES

  • FIGURE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 12. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ANTISENSE OLIGONUCLEOTIDES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MICRO INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SMALL INTERFERING RNAS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRATHECAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTRAVENOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ORAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBCUTANEOUS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY TOPICAL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CARDIOVASCULAR, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY IMMUNOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY METABOLIC DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY NEUROLOGICAL DISORDERS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY ONCOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OPHTHALMOLOGY, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RARE DISEASES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATIONS, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 60. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY PHARMACEUTICAL COMPANIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 61. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 62. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 63. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY RESEARCH LABORATORIES, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 64. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 65. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 66. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 68. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 69. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 70. AMERICAS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 71. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 74. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 75. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 76. NORTH AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 77. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 78. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 80. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 81. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 82. LATIN AMERICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE, MIDDLE EAST & AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 89. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 92. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 93. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 94. EUROPE ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 95. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 98. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 99. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 100. MIDDLE EAST ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 101. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 104. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 105. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 106. AFRICA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 107. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 108. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 109. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 110. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 112. ASIA-PACIFIC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 113. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 114. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 117. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 118. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 119. ASEAN ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 120. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 123. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 124. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 125. GCC ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 126. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 129. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 130. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 131. EUROPEAN UNION ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 132. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 135. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 136. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 137. BRICS ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 138. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 141. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 142. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 143. G7 ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 144. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 146. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 147. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 148. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 149. NATO ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 150. GLOBAL ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 151. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 154. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 155. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 156. UNITED STATES ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)
  • TABLE 157. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 158. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY OLIGONUCLEOTIDE TYPE, 2018-2032 (USD MILLION)
  • TABLE 159. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY INTERFERING RNAI, 2018-2032 (USD MILLION)
  • TABLE 160. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY MODE OF ADMINISTRATION, 2018-2032 (USD MILLION)
  • TABLE 161. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY THERAPEUTIC AREAS, 2018-2032 (USD MILLION)
  • TABLE 162. CHINA ANTISENSE & RNAI THERAPEUTICS MARKET SIZE, BY END USER, 2018-2032 (USD MILLION)